title: Post-transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: report of two cases and literature review.
abstract: Post-transplant lymphoproliferative disorder (PTLD) is one of the life-threatening complications after hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT), and it is associated almost exclusively with Epstein-Barr virus (EBV). We herein report 2 cases of EBV-associated PTLD after allogeneic HSCT localized in the adrenal gland. Both patients developed adrenal tumor within 3 months after HSCT and were successfully treated with rituximab or tapering immunosuppressive agents. Both remained alive without recurrence. A literature review revealed 12 reported cases of PTLD involving the adrenal gland, but the adrenal gland was involved as one of the lesions of advanced-stage PTLD after SOT. To the best of our knowledge, this is the first report to show cases of isolated EBV-associated adrenal PTLD after HSCT. PTLD should be recognized as one of the causes of isolated adrenal tumor after HSCT.
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kasahara
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Kato
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Koda
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kohashi
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kikuchi
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamane
authors.affiliation: Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Mikami
authors.affiliation: Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kameyama
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.affiliation: Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
mesh_terms: D000307:Adrenal Gland Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008297:Male; D000069283:Rituximab / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: Epstein-Barr virus; adrenal gland; allogeneic hematopoietic stem cell transplantation; post-transplant lymphoproliferative disorder; rituximab